Engineering a Radiohybrid PSMA Ligand with an Albumin-Binding Moiety and Pharmacokinetic Modulation via an Albumin-Binding Competitor for Radiotheranostics
Molecules · 2025
DOI: 10.3390/molecules30132804 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Saki Hirata und 9 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Ishikawa, Japan. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Albumins, Glutamate Carboxypeptidase II, Antigens, Surface. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI, The Mitani Foundation for Research and Development, Terumo life science foundation.
Abstract (Originalsprache)
The prostate-specific membrane antigen (PSMA) is a well-established target for radiotheranostics in prostate cancer. We previously demonstrated that 4-(p-astatophenyl)butyric acid (APBA), an albumin-binding moiety (ABM) labeled with astatine-211 (211At), enables the modulation of pharmacokinetics and enhancement of therapeutic efficacy when combined with the post-administration of an albumin-binding competitor. However, this strategy has not been explored in PSMA-targeting ligands. We designed and synthesized [211At]6, a novel PSMA ligand structurally analogous to PSMA-617 with APBA. The compound was obtained via a tin–halogen exchange reaction from the corresponding tributylstannyl precursor. Comparative cellular uptake and biodistribution studies were conducted with [211At]6, its radioiodinated analog [125I]5, and [67Ga]Ga-PSMA-617. To assess pharmacokinetic modulation, sodium 4-(p-iodophenyl)butanoate (IPBA), an albumin-binding competitor, was administered 1 h postinjection of [125I]5 and [211At]6 at a 10-fold molar excess relative to blood albumin. The synthesis of [211At]6 gave a radiochemical yield of 15.9 ± 7.7% and a radiochemical purity > 97%. The synthesized [211At]6 exhibited time-dependent cellular uptake and internalization, with higher uptake levels than [67Ga]Ga-PSMA-617. Biodistribution studies of [211At]6 in normal mice revealed a prolonged blood retention similar to those of [125I]5. Notably, post-administration of IPBA significantly reduced blood radioactivity and non-target tissue accumulation of [125I]5 and [211At]6. We found that ABM-mediated pharmacokinetic control was applicable to PSMA-targeted radiotherapeutics, broadening its potential for the optimization of radiotheranostics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Ishikawa, Japan.
- Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Fukushima, Japan.
- Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa University, Takara-machi 13-1, Kanazawa 920-8641, Ishikawa, Japan.
ORCID-Profile: Masayuki Munekane, Kenji Mishiro, Kohshin Washiyama, Takeshi Fuchigami, Kazuhiro Takahashi, Kazuma Ogawa
Förderung
- JSPS KAKENHI
- The Mitani Foundation for Research and Development
- Terumo life science foundation
- Program of the Network-type Joint Usage/Research Center for Radiation Disaster Medical Sci-ence
- Program of the Network-type Joint Usage/Research Center for Radiation Disaster Medical Science
Zitieren
APA
Hirata, S., Echigo, H., Munekane, M., Mishiro, K., Washiyama, K., Fuchigami, T., Wakabayashi, H., Takahashi, K., Kinuya, S., & Ogawa, K. (2025). Engineering a Radiohybrid PSMA Ligand with an Albumin-Binding Moiety and Pharmacokinetic Modulation via an Albumin-Binding Competitor for Radiotheranostics. Molecules. https://doi.org/10.3390/molecules30132804
Vancouver
Hirata S, Echigo H, Munekane M, Mishiro K, Washiyama K, Fuchigami T, et al. Engineering a Radiohybrid PSMA Ligand with an Albumin-Binding Moiety and Pharmacokinetic Modulation via an Albumin-Binding Competitor for Radiotheranostics. Molecules. 2025. doi:10.3390/molecules30132804
BibTeX
@article{Hirata2025,
author = {Hirata, Saki and Echigo, Hiroaki and Munekane, Masayuki and Mishiro, Kenji and Washiyama, Kohshin and Fuchigami, Takeshi and Wakabayashi, Hiroshi and Takahashi, Kazuhiro and Kinuya, Seigo and Ogawa, Kazuma},
title = {Engineering a Radiohybrid PSMA Ligand with an Albumin-Binding Moiety and Pharmacokinetic Modulation via an Albumin-Binding Competitor for Radiotheranostics},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30132804}
}
EUVIMED